吉首大学学报(自然科学版) ›› 2025, Vol. 46 ›› Issue (2): 78-89.DOI: 10.13438/j.cnki.jdzk.2025.02.010

• 医药 • 上一篇    下一篇

基于生物信息学分析MIA3在泛癌中的表达和临床意义

陈功华,欧鹏飞,甄瑶,夏杰,满竞
  

  1. (1.张家界市人民医院,湖南 张家界 427000;2.吉首大学医学院,湖南 吉首 416000;3.湖南师范大学医学院,湖南 长沙 410000)
  • 出版日期:2025-03-25 发布日期:2025-04-30
  • 作者简介:陈功华(1969—),男,湖南张家界人,张家界市人民医院副主任医师,学士,主要从事胃肠道肿瘤研究
  • 基金资助:
    张家界市科技发展专项项目(2022/09)

Differential Expression and Clinical Significance of MIA3 Based on Bioinformatics Analysis in Pan-Cancer

CHEN Gonghua1,OU Pengfei,ZHEN Yao1,3,XIA Jie1,MAN Jing   

  1. (1.People's Hospital of Zhangjiajie,Zhangjiajie 427000,Hunan China;2.School of Medicine,Jishou University,Jishou 416000,Hunan China;3.School of Medicine,Hunan Normal University,Changsha 410000,China)
  • Online:2025-03-25 Published:2025-04-30

摘要:为了探究MIA3在泛癌中的表达情况及作用,通过搜集TCGA等数据库,采用生物信息学方法揭示MIA3表达与泛癌临床预后及免疫的关联性.结果表明,MIA3在浸润性乳腺癌、膀胱尿路上皮癌、食管癌、头颈鳞状细胞癌、肾透明细胞癌、混合肾癌、肝细胞肝癌、肺腺癌、肺鳞癌、前列腺癌、胃癌、胃和食管癌中表达显著上调,在肾嫌色细胞癌和甲状腺癌中表达显著下调;子宫内膜癌的MIA3突变频率最高,达11.4%,胃癌次之,为6.1%;在大多数癌症(如卵巢浆液性囊腺癌、脑低级别胶质瘤、多形性胶质母细胞瘤、肾乳头状细胞癌、混合肾癌等)中,MIA3表达与DNA甲基化酶表达呈正相关关系;MIA3高表达是肾上腺皮质癌、肾嫌色细胞癌、肾乳头状细胞癌、混合肾癌、脑低级别胶质瘤等多种癌症的危险因子,会导致这些患者预后差,但在皮肤黑色素瘤和卵巢浆液性囊腺癌中,MIA3低表达会导致这些患者预后差;在多种癌症中,MIA3的表达与B细胞、CD4+T淋巴细胞、CD8+T淋巴细胞、中性粒细胞、树突状细胞、巨噬细胞的浸润明显相关;在结直肠癌、混合肾癌、头颈鳞状细胞癌、肾透明细胞癌、睾丸生殖细胞肿瘤、肾嫌色细胞癌中,MIA3表达与基质评分和免疫评分均呈正相关关系.MIA3可作为多种癌症的预后生物标志物和治疗新靶标,但仍需进一步研究验证.

关键词: MIA3, 泛癌, 生物信息学, 免疫细胞, 浸润

Abstract: To elucidate the expression profile and role of MIA3 in pan-cancer,we collected data from TCGA and other databases and employed bioinformatics methods to explore the associations between MIA3 and clinical prognosis as well as immune-related characteristics in various cancers.Results showed that MIA3 expression was significantly upregulated in invasive breast cancer,bladder urothelial carcinoma,esophageal cancer,head and neck squamous cell carcinoma,renal clear cell carcinoma,mixed renal cancer,hepatocellular carcinoma,lung adenocarcinoma,lung squamous cell carcinoma,prostate cancer,gastric cancer,and gastroesophageal cancer,while it was significantly downregulated in renal chromophobe carcinoma and thyroid carcinoma.The highest mutation frequency of MIA3 was observed in endometrial cancer (11.4%),followed by gastric cancer (6.1%).In most cancers,especially ovarian serous cystadenoma,brain low-grade glioma,glioblastoma multiforme,renal papillary cell carcinoma,and mixed renal cancer,MIA3 expression was positively correlated with DNA methyltransferase expression.High expression of MIA3 was a risk factor for poor prognosis in adrenocortical carcinoma,renal chromophobe carcinoma,renal papillary cell carcinoma,mixed renal cancer,and brain low-grade glioma.Conversely,low expression of MIA3 was associated with poor prognosis in cutaneous melanoma and ovarian serous cystadenoma.The infiltration of cancer immune cells,including B cells,CD4+T lymphocytes,CD8+T lymphocytes,neutrophils,dendritic cells,and macrophages,was significantly correlated with MIA3 expression.Additionally,MIA3 expression was positively correlated with stromal and immune scores in colorectal cancer,mixed renal cancer,head and neck squamous cell carcinoma,renal clear cell carcinoma,testicular germ cell tumors,and renal chromophobe carcinoma.These findings suggest that MIA3 may serve as a valuable prognostic biomarker and potential therapeutic target for multiple cancers.However,further studies are needed to confirm these findings

Key words: MIA3, pan-cancer, bioinformatics, immune cell, infiltration

公众号 电子书橱 超星期刊 手机浏览 在线QQ